{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:57:57Z","timestamp":1790657877087,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Nuclear protein in testis (NUT) midline carcinoma (NMC) is an extremely rare, highly aggressive, and poorly differentiated malignant neoplasm that predominantly arises from the midline epithelial structures of the head and neck. It is driven by genetic rearrangements of the NUTM1 gene, with the most common aberration being a translocation that forms a fusion gene with BRD4 on chromosome 19p13.1. The diagnosis of NMC is challenging due to its non-specific clinical and histological features, and it typically requires a combination of immunohistochemical detection of NUT protein and molecular assays to confirm NUTM1 gene rearrangement. The prognosis of NMC is dismal, with a median overall survival of less than one year. To date, no standard treatment regimen has been established, and only individualized therapeutic strategies have been reported in the literature. Herein, we present a case of a 40-year-old female patient with NMC of the left nasal cavity who presented with nasal mass, nasal obstruction, rhinorrhea, mild epistaxis, and hyposmia. The patient was diagnosed with NMC based on pathological and immunohistochemical findings, and was staged as T2N0M0. She received multidisciplinary treatment including neoadjuvant chemotherapy, radical surgery, adjuvant chemoradiotherapy, and subsequent immune checkpoint inhibitor (ICI) maintenance therapy. Up to the latest follow-up in February 2026, the patient had achieved complete remission with no evidence of tumor recurrence. We conclude that comprehensive and intensive first-line multidisciplinary therapy is crucial for improving clinical outcomes in patients with NMC, a disease with inherently high risks of recurrence and progression and a poor natural prognosis.<\/jats:p>","DOI":"10.3389\/fonc.2026.1859581","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:36:01Z","timestamp":1790656561000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Nuclear protein in testis midline carcinoma of nasal cavity: a case report and review of the literature"],"prefix":"10.3389","volume":"16","author":[{"given":"Kexin","family":"Meng","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Hospital of Qingdao University","place":["Qingdao, China"]},{"name":"Medical College, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Hospital of Qingdao University","place":["Qingdao, China"]},{"name":"Medical College, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Affiliated Hospital of Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.bulcan.2022.01.015","article-title":"Nut carcinoma in children, adolescents and young adults","volume":"109","author":"Lemelle","year":"2022","journal-title":"Bull Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.02.107","article-title":"Midline carcinoma of children and young adults with NUT rearrangement","volume":"22","author":"French","year":"2004","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cancergencyto.2010.06.007","article-title":"Nut midline carcinoma","volume":"203","author":"French","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0b013e318254ce54","article-title":"Nut midline carcinomas of the sinonasal tract","volume":"36","author":"Bishop","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-016-0763-0","article-title":"Nut midline carcinoma of the nasal cavity","volume":"11","author":"Edgar","year":"2017","journal-title":"Head Neck Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1053\/j.semdp.2021.06.005","article-title":"Nut carcinoma of the lung","volume":"38","author":"Lantuejoul","year":"2021","journal-title":"Semin Diagn Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-12-1153","article-title":"Clinicopathologic features and long-term outcomes of NUT midline carcinoma","volume":"18","author":"Bauer","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.052902","article-title":"Demystified molecular pathology of NUT midline carcinomas","volume":"63","author":"French","year":"2010","journal-title":"J Clin Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-017-0858-2","article-title":"Nut midline carcinoma: A series of five cases, including one with unusual clinical course","volume":"12","author":"Kakkar","year":"2018","journal-title":"Head Neck Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2017.10.011","article-title":"Sinonasal NUT carcinoma: clinicopathological and cytogenetic analysis with autopsy findings","volume":"71","author":"Minato","year":"2018","journal-title":"Hum Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22838","article-title":"Emerging entities in NUTM1-rearranged neoplasms","volume":"59","author":"Mcevoy","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2025.107392","article-title":"Long-term survival after multimodal treatment of sinonasal NUT carcinoma: a case report","volume":"166","author":"Rijken","year":"2025","journal-title":"Oral Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-024-08898-1","article-title":"Clinical analysis and treatment progress of NUT carcinoma in the nasal cavity and sinuses: a retrospective study from a single institution","volume":"282","author":"Gao","year":"2025","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-024-08489-0","article-title":"Therapeutic approaches to sinonasal NUT carcinoma: a systematic review","volume":"281","author":"Urbanelli","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112151-20221118-00975","article-title":"Clinicopathological analysis of nuclear protein in testis midline carcinoma","volume":"52","author":"Zhang","year":"2023","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12727","article-title":"Nut carcinoma: Clinicopathologic features, pathogenesis, and treatment","volume":"68","author":"French","year":"2018","journal-title":"Pathol Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.914031","article-title":"Nut carcinoma-an underdiagnosed malignancy","volume":"12","author":"Lauer","year":"2022","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/10668969211019532","article-title":"Challenging diagnosis in NUT carcinoma","volume":"29","author":"Claudia","year":"2021","journal-title":"Int J Surg Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-20-0087","article-title":"Combined targeting of the BRD4-NUT-p300 axis in NUT midline carcinoma by dual selective bromodomain inhibitor, NEO2734","volume":"19","author":"Morrison-Smith","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/genes12020235","article-title":"Challenges and opportunities in NUT carcinoma research","volume":"12","author":"Hakun","year":"2021","journal-title":"Genes (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2024.04.007","article-title":"Endoscopic surgery for sinonasal and skull base cancer","volume":"33","author":"Rodas","year":"2024","journal-title":"Surg Oncol Clin N Am"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-018-4882-y","article-title":"Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases","volume":"275","author":"Giridhar","year":"2018","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/mph.0000000000001860","article-title":"Metastatic NUT midline carcinoma treated with aggressive neoadjuvant chemotherapy, radiation, and resection: a case report and review of the literature","volume":"43","author":"Sopfe","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1631\/jzus.b2300492","article-title":"Immune checkpoint blockade for cancer therapy: current progress and perspectives","volume":"26","author":"Ye","year":"2025","journal-title":"J Zhejiang Univ-Sci B"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1412070","DOI":"10.3389\/fonc.2024.1412070","article-title":"Case report: Long term remission of metastatic sinonasal NUT carcinoma after palliative radiotherapy and immunotherapy in an elderly patient","volume":"14","author":"Ng","year":"2024","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1094770","article-title":"The whole treatment process and thinking of a patient with NUT carcinoma of the parotid gland: a case report","volume":"13","author":"Fu","year":"2023","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04621-5","article-title":"Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case","volume":"149","author":"Chen","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1632133","article-title":"Etoposide and cisplatin in combination with anlotinib for lung NUT carcinoma: a case report","volume":"15","author":"Sun","year":"2025","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1497124","article-title":"Pulmonary NUT carcinoma, an elusive and refractory entity, shows transient response to chemotherapeutics and PD-1 inhibitor: a case report and literature review","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1083_22","article-title":"Immunotherapy experience in sinonasal NUT midline carcinoma, case report","volume":"20","author":"Caner","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.e20518","article-title":"The efficacy and safety of a novel PD-1\/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: A multicenter retrospective observational study","volume":"15","author":"Li","year":"2024","journal-title":"Thorac Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4877551","article-title":"Cadonilimab (PD-1\/CTLA-4) in combination with lenvatinib in unresectable hepatocellular carcinoma (uHCC): A retrospective real-world study","volume":"10","author":"Yuan","year":"2024","journal-title":"Heliyon"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-1445","article-title":"Cadonilimab (a PD-1\/CTLA-4 bispecific antibody) plus neoadjuvant chemotherapy in locally advanced head and neck squamous cell carcinoma: a phase II clinical trial","volume":"31","author":"Cao","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12105-021-01406-5","article-title":"Update from the 5th edition of the World Health Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull base","volume":"16","author":"Thompson","year":"2022","journal-title":"Head Neck Pathol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1859581\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:36:15Z","timestamp":1790656575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1859581\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1859581"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1859581","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1859581"}}